Сурогатні армії та їх роль у сучасних воєнних операціях заходу на прикладі Афганістану, Іраку та Лівії

Стаття присвячена феномену сурогатних армій в сучасному світі та визначенню їхнього місця у воєнних операціях членів НАТО на прикладі кампаній 2001р. в Афганістані, 2003р. в Іраку та 2011р. в Лівії. Виділені загальні та специфічні особливості використання сурогатної військової сили в цих операціях. Проаналізована роль сурогатної компоненти в тріаді порівняно з роллю в ній військової авіації та спеціальних підрозділів західних країн. The article is devoted to the phenomenon of surrogate armies in the modern world and their place in the military operations of NATO as an example the campaign of 2001 in Afghanistan, 2003 in Iraq, 2011 in Libya. Allocated general and specific features of the use of surrogate military force in these operations. The role of surrogate components in the triad comparison with a role in its air forces and special forces of Western countries

Урбанізаційні процеси в столичних агломераціях Киргизстану та Таджикистану в пострадянський період та їх вплив на соціально-політичну сферу

Розглядаються урбанізаційні процеси в агломераціях Бішкеку та Душанбе у пострадянський період. Відзначається зростання населення цих агломерацій з суттєвою зміною етнічної структури їх населення протягом останніх двох десятиліть за рахунок заміщення „європейських” мешканців представниками титульної нації. Збільшення населення агломерацій відбувається не лише за рахунок їх центрів, а й за рахунок столичних пригородів, що призводить до значного збільшення забудованої місцевості та злиття Бішкеку та Душанбе з навколишніми населеними пунктами. Urban processes in the agglomerations of Bishkek and Dushanbe during the post-Soviet period are considered. Population growth of this agglomerations and considerable change in ethnic structures of their population during last two decades due to the substitution of „European" residents by the representatives of title nations are noted. The population growth of the agglomerations occurs not only owing to their centres, but also due to the capital suburbs that cause significant extension of built-up areas and merging of Bishkek and Dushanbe with surrounding communities

The Formation of a Power Multi-Pulse Extreme Ultraviolet Radiation in the Pulse Plasma Diode of Low Pressure

In this paper results are presented on experimental studies of the temporal characteristics of spike extreme ultraviolet (EUV) radiation in the spectral range of 12.2 ÷ 15.8 nm from the anode region of high-current (I = 40 kA) pulsed discharges in tin vapor. It is observed that the intense multi-spike radiation in this range arises at an inductive stage of the discharge. It has been shown that the radiation spikes correlate with the sharp increase of active resistance and of pumped power, due to plasma heating by an electron beam, formed in the double layer of charged particles. It has been observed that for large number of spikes the conversion efficiency of pumped energy into radiationat double layer formation is essentially higher in comparison with collisional heating

Microtopochemistry of pyrite nodules of siliceous siltstones from the Yubileinoe massive sulfide deposit (the Southеrn Urals): LA-IСP-MS data

Object . The zonal pyrite nodules and metacrystals from siliceous siltstones of ore-bearing horizon of the Second ore body from the Yubileynoe massive sulfide deposit are studied. Materials and methods . We used 9 samples and 15 polished sections of siliceous siltstones with pyrite mineralization. Analysis of chemical composition minerals was determined by Tescan Vega 3 with an energy dispersive microprobe Oxford Instruments X-act (Institute of Mineralogy UB RAS, Miass). Quantitave LA-ICP-MS analysis of pyrite for major and trace elements was carried out using New Wave Research UP-213 laser microprobe coupled to an Agilent 7500 quadrupole ICP-MS housed (University of Tasmania, Australia). Results. Microtopochemistry was established that the diagenetic core of the nodule is characterized by trace elements of typical poikilites of quartz (Si) and alumosilicates (Si, Al, Mg, V, Cr, K, Na, Ca), rutile and titanite (Ti), inclusions of chalcopyrite (Cu), sphalerite (Zn), galena (Pb, Sb, Bi), tetrahedrite-tennantite (As, Sb), native gold, petzite, hessite (Au, Ag, Te), tellurobismuthite, altaite, and coloradoite (Te, Bi, Pb). Cobalt and Ni substitute for Fe2+. The rim of subhedral pyrite is depleted in most trace elements except for Ni and As. Subhedral pyrite became rich in chalcophile (Au, Ag, Sb, Bi, Cu, Zn, Hg) and lithophile (Ca, K, Na, Cr) elements at the final stage of growth of the nodule. Similar mineralogical and geochemical zonation is typical of the pyrite metacrystals, where a micro-grained core concentrates Pb, Bi and Te, and a rim of subhedral pyrite is depleted in most trace elements. Similarly to the nodules, the outer rim of pyrite metacrystals is enriched in most trace elements (Pb, Au, Ag, Sb, Cu, As, Mo, Cr, etc.). The nodules and metacrystals were formed from diagenetic micronodule of poikilite pyrite. Conclusions. It is suggested that mineralogical and geochemical differences in pyrite metacrystals and nodules are caused by the greater degree of development of rims of subhedral pyrite

The Formation of a Power Multi-Pulse Extreme Ultraviolet Radiation in the Pulse Plasma Diode of Low Pressure

In this paper results are presented on experimental studies of the temporal characteristics of spike extreme ultraviolet (EUV) radiation in the spectral range of 12.2 ÷ 15.8 nm from the anode region of high-current (I = 40 kA) pulsed discharges in tin vapor. It is observed that the intense multi-spike radiation in this range arises at an inductive stage of the discharge. It has been shown that the radiation spikes correlate with the sharp increase of active resistance and of pumped power, due to plasma heating by an electron beam, formed in the double layer of charged particles. It has been observed that for large number of spikes the conversion efficiency of pumped energy into radiationat double layer formation is essentially higher in comparison with collisional heating

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

To compare the efficacy and safety of SB4 (an etanercept biosimilar) with reference product etanercept (ETN) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) therapy. METHODS:This is a phase III, randomised, double-blind, parallel-group, multicentre study with a 24-week primary endpoint. Patients with moderate to severe RA despite MTX treatment were randomised to receive weekly dose of 50 mg of subcutaneous SB4 or ETN. The primary endpoint was the American College of Rheumatology 20% (ACR20) response at week 24. Other efficacy endpoints as well as safety, immunogenicity and pharmacokinetic parameters were also measured. RESULTS: 596 patients were randomised to either SB4 (N=299) or ETN (N=297). The ACR20 response rate at week 24 in the per-protocol set was 78.1% for SB4 and 80.3% for ETN. The 95% CI of the adjusted treatment difference was -9.41% to 4.98%, which is completely contained within the predefined equivalence margin of -15% to 15%, indicating therapeutic equivalence between SB4 and ETN. Other efficacy endpoints and pharmacokinetic endpoints were comparable. The incidence of treatment-emergent adverse events was comparable (55.2% vs 58.2%), and the incidence of antidrug antibody development up to week 24 was lower in SB4 compared with ETN (0.7% vs 13.1%). CONCLUSIONS:SB4 was shown to be equivalent with ETN in terms of efficacy at week 24. SB4 was well tolerated with a lower immunogenicity profile. The safety profile of SB4 was comparable with that of ETN

Dapagliflozin and cardiovascular outcomes in type 2 diabetes

BACKGROUND The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium– glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS We randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease to receive either dapagliflozin or placebo. The primary safety outcome was a composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke. The primary efficacy outcomes were MACE and a composite of cardiovascular death or hospitalization for heart failure. Secondary efficacy outcomes were a renal composite (≥40% decrease in estimated glomerular filtration rate to <60 ml per minute per 1.73 m2 of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes) and death from any cause. RESULTS We evaluated 17,160 patients, including 10,186 without atherosclerotic cardiovascular disease, who were followed for a median of 4.2 years. In the primary safety outcome analysis, dapagliflozin met the prespecified criterion for noninferiority to placebo with respect to MACE (upper boundary of the 95% confidence interval [CI], <1.3; P<0.001 for noninferiority). In the two primary efficacy analyses, dapagliflozin did not result in a lower rate of MACE (8.8% in the dapagliflozin group and 9.4% in the placebo group; hazard ratio, 0.93; 95% CI, 0.84 to 1.03; P=0.17) but did result in a lower rate of cardiovascular death or hospitalization for heart failure (4.9% vs. 5.8%; hazard ratio, 0.83; 95% CI, 0.73 to 0.95; P=0.005), which reflected a lower rate of hospitalization for heart failure (hazard ratio, 0.73; 95% CI, 0.61 to 0.88); there was no between-group difference in cardiovascular death (hazard ratio, 0.98; 95% CI, 0.82 to 1.17). A renal event occurred in 4.3% in the dapagliflozin group and in 5.6% in the placebo group (hazard ratio, 0.76; 95% CI, 0.67 to 0.87), and death from any cause occurred in 6.2% and 6.6%, respectively (hazard ratio, 0.93; 95% CI, 0.82 to 1.04). Diabetic ketoacidosis was more common with dapagliflozin than with placebo (0.3% vs. 0.1%, P=0.02), as was the rate of genital infections that led to discontinuation of the regimen or that were considered to be serious adverse events (0.9% vs. 0.1%, P<0.001). CONCLUSIONS In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure. (Funded by AstraZeneca; DECLARE–TIMI 58 ClinicalTrials.gov number, NCT01730534.

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes

Aims: To assess the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes enrolled in the CANagliflozin cardioVascular Assessment Study (CANVAS) who were on an incretin mimetic [dipeptidyl peptidase-4 (DPP-4) inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist]. Methods: CANVAS is a double-blind, placebo-controlled study that randomized participants to canagliflozin 100 or 300 mg or placebo added to routine therapy. The present post hoc analysis assessed the efficacy and safety of canagliflozin 100 and 300 mg compared with placebo in subsets of patients from CANVAS who were taking background DPP-4 inhibitors or GLP-1 receptor agonists with or without other antihyperglycaemic agents at week 18. Results: Of the 4330 patients in CANVAS, 316 were taking DPP-4 inhibitors and 95 were taking GLP-1 receptor agonists. At 18 weeks, canagliflozin 100 and 300 mg provided larger placebo-subtracted reductions in glycated haemoglobin (HbA1c) in patients taking DPP-4 inhibitors [-0.56% (95% confidence interval [CI]: -0.77, -0.35), and -0.75% (95% CI: -0.95, -0.54), respectively] and GLP-1 receptor agonists [-1.00% (95% CI: -1.35, -0.65), and -1.06% (95% CI: -1.43, -0.69), respectively]. Body weight and blood pressure (BP) reductions were seen with canagliflozin versus placebo in both subsets. Higher incidences of genital mycotic infections and osmotic diuresis-related adverse events (AEs) were seen with canagliflozin compared with placebo. The incidence of hypoglycaemia was numerically higher with canagliflozin versus placebo; nearly all events occurred in patients on background insulin or insulin secretagogues. Conclusions: In patients on background incretin mimetics, canagliflozin improved HbA1c, body weight and BP, with an increased incidence of AEs related to SGLT2 inhibition

Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: Subgroup analysis of the DISTINCT randomised trial

The DISTINCT study (reDefining Intervention with Studies Testing Innovative Nifedipine GITS - Candesartan Therapy) investigated the efficacy and safety of nifedipine GITS/candesartan cilexetil combinations vs respective monotherapies and placebo in patients with hypertension. This descriptive sub-analysis examined blood pressure (BP)-lowering effects in high-risk participants, including those with renal impairment (estimated glomerular filtration rate<90 ml min-1, n=422), type 2 diabetes mellitus (n=202), hypercholesterolaemia (n=206) and cardiovascular (CV) risk factors (n=971), as well as the impact of gender, age and body mass index (BMI). Participants with grade I/II hypertension were randomised to treatment with nifedipine GITS (N) 20, 30, 60 mg and/or candesartan cilexetil (C) 4, 8, 16, 32 mg or placebo for 8 weeks. Mean systolic BP and diastolic BP reductions after treatment in high-risk participants were greater, overall, with N/C combinations vs respective monotherapies or placebo, with indicators of a dose-response effect. Highest rates of BP control (ESH/ESC 2013 guideline criteria) were also achieved with highest doses of N/C combinations in each high-risk subgroup. The benefits of combination therapy vs monotherapy were additionally observed in patient subgroups categorised by gender, age or BMI. All high-risk participants reported fewer vasodilatory adverse events in the pooled N/C combination therapy than the N monotherapy group. In conclusion, consistent with the DISTINCT main study outcomes, high-risk participants showed greater reductions in BP and higher control rates with N/C combinations compared with respective monotherapies and lesser vasodilatory side-effects compared with N monotherapy